Altimmune Inc (ALT., a U.S.-based biotechnology company dedicated to the development of drugs for obesity and liver disease**US) announced the results of an extremely optimistic interim study of its blockbuster trial** drug** pemvidutide, and the company's stock price was at one point** about 66% in after-hours trading in the U.S. stock market. The company said on Thursday local time that in a 48-week trial, the highest dose of the drug helped obese patients lose up to 16% of their body weight, or 322 pounds.
It is understoodAltimmune's positive trial results put it on par with the Danish pharmaceutical giant Novo Nordisk A's Wegovy, which helped obese patients lose about 15% of their body weight in a 68-week trial.
Currently,The biggest threat to Wegovy is undoubtedly Tirzepatide, a subsidiary of the American pharmaceutical giant Eli Lilly, which, unlike liraglutide and semaglutide, which use single GLP-1 receptor agonists, binds both GLP-1R and the GiP receptor. Pevitide, which Altimmune is researching, is actually a dual agonist, combining GLP-1R and GCGR.
In the results of the trial, the combination of this double agonist showed a balanced high potency, and the hypoglycemic and ** effects were further improved compared with Novo Nordisk's Wegovy. Trial data showed that 29-51% of patients with tezepatide** had a reduction in glycosylated hemoglobin levels (the main measure of blood glucose) by as much as 57%, compared with only 20% of the population with semaglutide reaching this indicator.
*In terms of efficacy, a comparative analysis conducted by Truveta Research, a medical data and analytics company, showed that in about 1In a sample of 80,000 overweight or obese patients, those who used tirzepatide were more likely to lose 15% of their body weight than those who used wegovy. The average fat loss effect of tirzepatide over a three-month period was 59% compared to 3 for Wegovy6%γAt the marker point in the one-year period, patients who received tirzepatide** lost an average of 152% compared to 7 in the Wegovy group9%γ
Altimmune has made a difference
Pharmaceutical companies around the world are racing to replicate the success of Novo Nordisk and its current most formidable competitor, Eli Lilly, which has been used to achieve rapid weight loss and generate epic sales. Some of these drugmakers are advancing their products into clinical trials, while others are considering acquiring smaller companies that have already achieved promising positive results.
Altimmune's pevitide is actually a dual agonist, but combines GLP-1R and GCGR, while Eli Lilly tizepatide binds both GLP-1R and the GIP receptor. The 48-week trial data released by Altimmune on Thursday local time is gratifying, and the weight loss in all dose groups has seen a significant increase, which is almost at the same level as the effect of the Wegovy trial of Novo Nordisk, and shows a dose correlation.
As of press time, Altimmune's stock price rose 3892% to 4$390, giving back some of the earlier gains. As of Thursday**, the Gaithersburg, Maryland-based company had a market capitalization of nearly $1$700 million, with Novo Nordisk's market capitalization of up to $450 billion, and the American pharmaceutical giant Eli Lilly (Lly.).US) is as small as $560 billion.
Altimmune said that patients who underwent the Altimmune trial continued to lose weight after the end of the trial, while their blood pressure dropped and their heart rate did not increase significantly, which was different from what was observed in some other drug trials. At the maximum of 2At a dose of 4 mg, almost one-third of the trial participants lost 20% or more of their body weight, and 2The weight loss trajectory at the end of the 4 mg dose** suggests that continuing** can lead to greater weight loss.
Altimmune said the most common*** were nausea and vomiting, with only one patient experiencing serious complications. Scott Harris, the company's chief medical officer, said in a statement: "In this trial, the 48-week level of weight loss has been shown to fully reverse the major complications caused by obesity. "The company is developing drugs for both obesity and a severe liver disease.
Altimmune's management will hold a ** meeting on Friday morning local time to discuss the trial results.
**The future of medicine is extremely promising!Wall Street money flocked to Eli Lilly and Novo Nordisk
According to the latest 13F documents disclosed by Wall Street financial institutions, due to the growth of global consumer demand for the "miracle drug" of the two major pharmaceutical giants - Eli Lilly and Novo Nordisk, Wall Street financial giants can be described as "smashing real money" in the **market** to vigorously support these two pharmaceutical giants, and are extremely optimistic about the stock price prospects of these two companies.
The latest 13F filings show that JPMorgan Chase, BlackRock, Vanguard, Two Sigma, Tiger Global Management and Coatue Management significantly increased their allocations to Eli Lilly in the third quarter. JPMorgan Chase & Co. alone has increased its holdings by more than 1.6 million shares, and currently holds a ** interest worth about $1 billion.
At the same time, global asset managers such as Fidelity Investments, Lazard Asset Management, T Rowe Price and Soros Fund** have all significantly increased their holdings of Novo Nordisk's ADR in the U.S. market.
Analysts at Wall Street giant Goldman Sachs expect annual sales of the global obesity drug market to likely grow to around $100 billion by 2030, up from $6 billion earlier this year. Goldman Sachs' is based on the fact that approximately 15 million U.S. adults will receive anti-obesity drugs for chronic management in 2030, compared to about 10.5 billion adults who are obese or overweight. Analysts excluded people with diabetes from obesity**. The World Obesity Federation (WOF) estimates that by 2035, more than 4 billion people β more than half of the world's population β may be living with varying degrees of obesity.
According to DataHorizzon Research, the drug market size is expected to be approximately $1.9 billion in 2022 and is expected to approach $90 billion by 2032, at a compound annual growth rate (CAGR) of approximately 50%.
So far this year, Novo Nordisk and Eli Lilly have risen 48% and 61% respectively in the U.S., significantly outperforming the S&P 500, the benchmark stock index for U.S. stocks.